Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beximco Sees Consistent Double-Digit Growth

Enters New Markets Including Oman, Lebanon, Venezuela, Bolivia And Kosovo

Executive Summary

Bangladesh’s Beximco reported double-digit growth both domestically and abroad in its financial first half, while continuing to expand in other international markets. Given its new launches and a COVID-19 vaccine distribution deal, the company remains optimistic about its future performance.

You may also be interested in...



Beximco’s Global Expansion Leads To Export Rise

Bangladesh’s Beximco has reported growth in export sales on the back of the company’s expansion into new international markets. The company delivered strong financial results overall for the third quarter of fiscal 2021, including double-digit growth on the domestic front. 

Beximco Takes Control Of Sanofi Bangladesh

Beximco has struck a deal worth nearly $50m to acquire a majority stake in Sanofi Bangladesh, allowing the firm to expand in its domestic market.

Aurobindo Announces Vaccine Partnership For India

Aurobindo has partnered with US based Covaxx for the first-ever peptide-based COVID-19 vaccine for the Indian market. While Dr Reddy’s has filed for favipiravir in Canada, Cipla has launched its second antigen detection test kit in India. And the Serum Institute of India will be providing Bangladesh with Oxford-AstraZeneca vaccine doses via Beximco

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel